Ergomed PLC (LON:ERGO)‘s stock had its “buy” rating reaffirmed by analysts at Numis Securities Ltd in a report issued on Monday. They currently have a GBX 267 ($3.25) price target on the stock. Numis Securities Ltd’s price objective would indicate a potential upside of 122.50% from the stock’s current price.
Several other analysts have also commented on ERGO. Stifel Nicolaus reaffirmed a “buy” rating and set a GBX 271 ($3.30) price target on shares of Ergomed PLC in a research report on Thursday, September 22nd. N+1 Singer reaffirmed a “buy” rating on shares of Ergomed PLC in a research report on Monday, September 26th.
Shares of Ergomed PLC (LON:ERGO) opened at 120.00 on Monday. The stock’s 50 day moving average price is GBX 120.18 and its 200 day moving average price is GBX 130.63. The stock’s market cap is GBX 37.34 million. Ergomed PLC has a one year low of GBX 117.00 and a one year high of GBX 172.00.
About Ergomed PLC
Ergomed PLC is a United Kingdom-based provider of drug development services to the pharmaceutical industry. The Company’s therapeutic focus is on onology, neurology and immunology and the development of orphan drugs. Ergomed Plc manages clinical development from Phase I through to late phase programs.
Receive News & Ratings for Ergomed PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed PLC and related companies with MarketBeat.com's FREE daily email newsletter.